Latest research on Xarelto

Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.

Xarelto interactions

In 4 of the 5 patients Coumadin was used in long term with the INR targeted between 2 and 3 and one patient was given Pradaxa 150 mg twice per day after 90 days of enoxaparin, while in 1 patient, Coumadin was later supplanted by Xarelto, 20 mg/day. [source, 2015]
In one patient (number 1), after 3 years on Coumadin, therapy was switched to Xarelto, 20 mg/day. [source, 2015]
When anticoagulation therapy had to be concurrently used, oral vitamin K2 therapy was ceased before use of Warfarin and dropped out from study; sometimes rivaroxaban (Xarelto, Bayer) was used to continue vitamin K therapy. [source, 2015]
According to the website Institute for Safe Medication Practices [7], warfarin (Coumadin) and newcomers Dabigatran (Pradaxa) and rivaroxaban (Xarelto) counted for 1734 reports to the FDA in the 2nd quarter of 2012, including 233 patient deaths, reinforcing the conclusion that anticoagulants rank among the highest risk of all outpatient drug treatments. [source, 2015]
Three molecules are currently available in the clinical setting: dabigatran etexilate (Pradaxa, Boehringer-Ingelheim Pharma GmBH, Ingelheim am Rhein, Germany): 75 mg, 110 mg, and 220 mg capsules, rivaroxaban (Xarelto, Johnson and Johnson/Bayer HealthCare AG, Leverkusen, Germany): 2.5 mg, 10 mg, 15 mg, and 20 mg tablets, and apixaban (Eliquis, Bristol Myers Squibb/Pfizer, Bristol Myers Squibb House, Uxbridge, United Kingdom): 2.5 mg and 5 mg tablets. [source, 2014]
With the arrival of a new generation of oral anticoagulants—direct factor Xa inhibitors rivaroxaban (Xarelto) and Dabigatran (Pradaxa) and the direct thrombin inhibitor apixaban (Eliquis)—many of these burdens on both the patient and the healthcare system have been alleviated. [source, 2014]
Dabigatran etexilate (Pradaxa, Boehringer Ingelheim) [8], rivaroxaban (Xarelto, Bayer HealthCare) [9], and apixaban (Eliquis, Bristol Myers Squibb) [10] are new oral anticoagulants (NOAC) available in Europe and other countries. [source, 2013]
Dabigatran etexilate (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis) are new oral anticoagulants (NOACs) that are approved in North America for reducing the risk of venous thromboembolism after hip or knee replacement and for stroke prevention in non-valvular atrial fibrillation. [source, 2013]
Currently, new generations of anticoagulants like Pradaxa and Xarelto are available as well. [source, 2012]